Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics - Seite 2

Activation of immune cells is an important process in the development of atherosclerosis and contributes to cardiovascular risk. The findings published in this article highlight the central role of BET proteins in driving the expression of disease risk factors in patients with diabetes and cardiovascular disease. Apabetalone treatment, acting at the epigenetic level, can reduce the activation of disease-promoting cells, helping us better understand how BET inhibitors reduce cardiovascular and chronic kidney disease risk in type 2 diabetes patients.

Event Reminder – AHA Scientific Sessions, November 13-17, 2020

Through participation at leading industry events, including the AHA Scientific Sessions, the Company continues to highlight apabetalone and its ability to regulate multiple biological pathways that underlie chronic disease, as well as presenting new research related to COVID-19. Further details of the presentations are outlined below, and the posters may be found HERE, when available.

• Oral Presentation: BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes from Patients with Cardiovascular Disease and Type 2 Diabetes
  • Presentation will discuss the important role of macrophage hyperactivation in driving CVD in diabetic patients and demonstrate apabetalone’s reduction of maladaptive gene expression in these cells
• Poster Presentation: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry
  • New data will be presented showing apabetalone treatment reduces expression of the angiotensin converting enzyme 2 (ACE2) receptor that is essential for SARS-CoV-2 viral entry, in human cell lines
• Poster Presentation: Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial
  • A new post-hoc analysis of BETonMACE will be presented examining the risk of major adverse cardiovascular events (MACE) events to enrolled patients according to their concomitant insulin treatment

About Resverlogix